Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
- 1 April 2013
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (suppl 2) , ii2-ii34
- https://doi.org/10.1136/annrheumdis-2013-203348
Abstract
As in previous years, the consensus group to consider the use of biological agents in the treatment of rheumatic diseases met during the 13th Annual Workshop on Advances in Targeted Therapies in March 2012. The group comprised rheumatologists from a number of universities among the continents of Europe, North America, South America, Australia and Asia.Keywords
This publication has 497 references indexed in Scilit:
- Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritisArthritis Care & Research, 2012
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJAMA, 2011
- Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial dataArthritis Care & Research, 2010
- Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti–hepatitis B core antigen positive) with rheumatic diseasesArthritis Care & Research, 2010
- Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics registerArthritis Care & Research, 2010
- Two‐year clinical and radiographic results with combination etanercept–methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two‐year, double‐blind, randomized studyArthritis & Rheumatism, 2010
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006